Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$58 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
0
ROE
-0.79 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.37
CFO
$-190.96 Mln
EBITDA
$-251.29 Mln
Net Profit
$-248.24 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
IO Biotech Inc (IOBT)
| -5.43 | -6.56 | 14.59 | -47.27 | -38.44 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
IO Biotech Inc (IOBT)
| -50.78 | -18.26 | -64.06 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.43 | 10,257.64 | 20.82 | 23.13 | |
| 33.74 | 13,384.89 | -- | -28.77 | |
| 109.59 | 11,042.16 | 33.66 | 14.16 | |
| 75.85 | 9,430.55 | 41.53 | 19.71 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target... immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Address: Ole MaalOees Vej 3, Copenhagen, Denmark, 2200 Read more
Founder, President, CEO, Principal Financial Officer & Director
Dr. Mai-Britt Zocca Ph.D.
Chief Medical Officer
Dr. Qasim Iftikhar Ahmad M.D.
Headquarters
Copenhagen
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of IO Biotech Inc (IOBT) stood at $ 106 Mln as on 30-Sep-24
The share price of IO Biotech Inc (IOBT) is $0.87 (NASDAQ) as of 18-Mar-2025 14:35 EDT. IO Biotech Inc (IOBT) has given a return of -38.44% in the last 3 years.
IO Biotech Inc (IOBT) has a market capitalisation of $ 58 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of IO Biotech Inc (IOBT) is 0.79 times as on 17-Mar-2025, a 71% discount to its peers’ median range of 2.69 times.
Since, TTM earnings of IO Biotech Inc (IOBT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the IO Biotech Inc (IOBT) and enter the required number of quantities and click on buy to purchase the shares of IO Biotech Inc (IOBT).
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Address: Ole MaalOees Vej 3, Copenhagen, Denmark, 2200
The CEO & director of Dr. Mai-Britt Zocca Ph.D.. is IO Biotech Inc (IOBT), and CFO & Sr. VP is Dr. Qasim Iftikhar Ahmad M.D..
There is no promoter pledging in IO Biotech Inc (IOBT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| IO Biotech Inc (IOBT) | Ratios |
|---|---|
|
Return on equity(%)
|
-96.09
|
|
Operating margin(%)
|
-8474.14
|
|
Net Margin(%)
|
-8138.74
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of IO Biotech Inc (IOBT) was $0 Mln.
$-0.05
(
